https://doi.org/10.48047/AFJBS.6.Si3.2024.3291-3306

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com



Research Paper Open Access

Solid Lipid Nanoparticles for Pulmonary Arterial Hypertension: Enhancing Solubility and Bioavailability of Lipophilic Phytoconstituents

Siddharth Dhaka[1], Harsh Rastogi[1]*, Anupama Patel[2], Ankur Gupta[3]

[1*]Assistant Professor, Department of Pharmaceutics, Dr K.N. Modi Institute of Pharmaceutical Education and Research Modinagar, Ghaziabad Uttar Pradesh
[2]Assistant Professor, Venkateshwara College of Pharmacy, Venkateshwara Group of Institutions, Meerut Uttar Pradesh
[3]Assistant ProfessorDepartment of Quality Assurance, Venkateshwara College of Pharmacy, Venkateshwara Group of Institution, Meerut

Corresponding author: Harsh Rastogi
Assistant Professor, Department of Pharmaceutics, Dr K.N. Modi Institute of Pharmaceutical Education and Research Modinagar, Ghaziabad Uttar Pradesh

ArticleInfo

Volume6, Issue Si3,July2024

Received: 30 May2024

Accepted:28 June 2024

Published:23 July2024

doi:

10.48047/AFJBS.6.Si3.2024.3291-3306

ABSTRACT:

Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease characterized by elevated blood pressure in the pulmonary arteries, leading to right heart failure and high mortality rates. Conventional treatments are often limited by poor solubility and bioavailability of therapeutic agents, especially lipophilic phytoconstituents such as curcumin and quercetin, which have shown potential in mitigating PAH symptoms. Solid lipid nanoparticles (SLNs) have emerged as promising nanocarriers that can enhance the solubility and bioavailability of these lipophilic compounds. SLNs are submicron-sized particles composed of biocompatible and biodegradable lipids that encapsulate lipophilic phytoconstituents, protecting them from degradation and improving their pharmacokinetic profiles. This review explores the formulation techniques, characterization, and clinical applications of SLNs in the context of PAH. Key preparation methods, including high shear homogenization, ultrasonication, and solvent emulsification-evaporation, are discussed, alongside strategies for optimizing particle size, zeta potential, and encapsulation efficiency. Clinical translation of SLNs remains challenging due to scalability, reproducibility, and regulatory hurdles. However, advances in targeted delivery systems and personalized medicine approaches hold promise for overcoming these barriers. This review highlights the potential of SLNs to revolutionize PAH treatment by enhancing the solubility and bioavailability of lipophilic phytoconstituents, paving the way for more effective and safer therapeutic options.

Keywords Solid Lipid Nanoparticles (SLNs), Pulmonary Arterial Hypertension (PAH), Lipophilic Phytoconstituents, Curcumin, Quercetin, Solubility Enhancement

1. Introduction

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by high blood pressure in the arteries that supply the lungs[1]. This condition arises from the narrowing or blockage of these arteries, leading to increased vascular resistance. As a result, the right side of the heart works harder to pump blood through the lungs, eventually causing right heart failure if left untreated[2,3]. The pathophysiology of PAH involves a complex interplay of genetic predisposition, endothelial dysfunction, vascular remodeling, inflammation, and thrombosis[4]. These processes lead to the proliferation of smooth muscle cells and fibroblasts, increased production of vasoconstrictors like endothelin-1, and reduced levels of vasodilators such as nitric oxide and prostacyclin[5]. The progressive nature of PAH results in increased pulmonary vascular resistance, which places a significant burden on the heart and leads to the characteristic symptoms of PAH, including shortness of breath, fatigue, chest pain, and syncope[6].The management of PAH includes a variety of pharmacological treatments aimed at alleviating symptoms, improving quality of life, and slowing disease progression[7,8]. Current treatment options include endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5 inhibitors), prostacyclin analogs, and soluble guanylate cyclase stimulators[9]. While these therapies can provide significant symptomatic relief and improve exercise capacity, they are often associated with limitations such as variable patient response, side effects, and the inability to reverse disease progression[10]. Additionally, many of these drugs have poor oral bioavailability, necessitating frequent dosing or invasive administration methods, which can lead to reduced patient compliance. The need for more effective and patient-friendly therapeutic strategies is paramount, highlighting the potential role of novel drug delivery systems and alternative therapeutic agents[11].

Importance of Lipophilic Phytoconstituents in PAH Treatment

Phytoconstituents, derived from medicinal plants, have garnered attention for their potential therapeutic effects in various diseases, including PAH[12]. Lipophilic phytoconstituents such as curcumin (from turmeric) and quercetin (a flavonoid found in many fruits and vegetables) are particularly promising due to their anti-inflammatory, antioxidant, and vasodilatory properties. Curcumin, for instance, has been shown to inhibit inflammatory pathways and reduce oxidative stress, which are key contributors to PAH pathogenesis[3,6]. Quercetin, on the other hand, exhibits vasodilatory effects through the modulation of nitric oxide production and has been demonstrated to prevent endothelial dysfunction and vascular remodeling[12]. These natural compounds offer a multifaceted approach to targeting the underlying mechanisms of PAH, providing a complementary strategy to conventional pharmacotherapy[13].Despite their therapeutic potential, the clinical application of lipophilic phytoconstituents is significantly hindered by their poor solubility and bioavailability. Lipophilicity, while beneficial for cell membrane permeability, poses challenges for aqueous solubility, leading to poor absorption and low bioavailability when administered orally[14]. Curcumin, for example, has low aqueous solubility and is rapidly metabolized and eliminated from the body, resulting in minimal systemic availability[15]. Quercetin faces similar challenges, with poor water solubility and extensive first-pass metabolism limiting its therapeutic efficacy[16]. These pharmacokinetic drawbacks necessitate high doses to achieve therapeutic concentrations, which can increase the risk of side effects and reduce patient compliance. Enhancing the solubility and bioavailability of these compounds is crucial to unlocking their full therapeutic potential[17]. This is where advanced drug delivery systems, such as solid lipid nanoparticles (SLNs), come into play. SLNs can encapsulate lipophilic phytoconstituents, protect them from degradation, and enhance their solubility and bioavailability, offering a promising solution to the challenges faced in PAH treatment[18].

2. Solid Lipid Nanoparticles (SLNs)

Solid lipid nanoparticles (SLNs) are submicron-sized particles, typically ranging from 50 to 1000 nanometers, composed of biocompatible and biodegradable lipids[19]. The core of SLNs is made of solid lipids at room and body temperatures, which distinguishes them from other lipid-based nanoparticles such as liposomes and nanoemulsions that have liquid cores[20]. This solid core can encapsulate lipophilic drugs, protecting them from degradation and enhancing their stability[21]. The outer shell of SLNs is stabilized by surfactants, which prevent particle aggregation and improve dispersion in aqueous media. The lipids used in SLNs can include triglycerides, fatty acids, steroids, and waxes, while common surfactants include phospholipids, bile salts, and non-ionic surfactants like polysorbates and poloxamers[10]. The choice of lipids and surfactants significantly influences the properties of SLNs, such as particle size, drug loading capacity, and release profile[22,4].

Types of Lipids and Surfactants Used

Lipids employed in SLNs are chosen based on their melting point, crystallinity, and compatibility with the encapsulated drug. Commonly used lipids include glyceryl monostearate, glyceryl behenate, stearic acid, and cetylpalmitate[23,3]. These lipids form a solid matrix that can encapsulate the drug molecules, enhancing their stability and controlled release. Surfactants stabilize the lipid core and can be selected based on their ability to reduce surface tension and prevent aggregation[24]. Phospholipids such as lecithin and synthetic surfactants like Poloxamer 188 are frequently used due to their excellent biocompatibility and stabilizing properties[5]. The combination of specific lipids and surfactants is tailored to optimize the physical and chemical characteristics of the SLNs for a given therapeutic application[7].



Fig. 1 Schematic representation of types of solid lipid nanoparticles

Advantages Over Other Nanocarriers

Enhanced Stability One of the primary advantages of SLNs over other nanocarriers is their enhanced stability. The solid lipid core of SLNs provides a rigid matrix that can protect encapsulated drugs from chemical and physical degradation, such as hydrolysis and oxidation[25]. This stability is particularly beneficial for sensitive compounds, including lipophilic phytoconstituents, which are prone to degradation in aqueous environments. The solid nature of the lipid core also reduces the mobility of drug molecules within the nanoparticles, minimizing drug leakage and ensuring a more consistent and prolonged therapeutic effect[26,10].

Controlled Release Properties SLNs offer superior controlled release properties compared to other nanocarriers. The solid lipid matrix can be engineered to modulate the release rate of the encapsulated drug, providing sustained and controlled release profiles[27]. This

controlled release is achieved through the diffusion of the drug from the solid lipid matrix and the gradual erosion of the lipid core. By adjusting the composition and crystallinity of the lipids, as well as the type and concentration of surfactants, it is possible to fine-tune the release kinetics to meet specific therapeutic needs[12]. This controlled release can enhance the bioavailability of lipophilic drugs, reduce dosing frequency, and improve patient compliance[28,9].

Biocompatibility and Biodegradability SLNs are composed of biocompatible and biodegradable materials, making them safe and well-tolerated in the body. The lipids and surfactants used in SLNs are typically derived from natural sources or are approved for pharmaceutical use, minimizing the risk of adverse reactions[29]. Upon administration, SLNs are gradually degraded by enzymatic processes in the body, and the degradation products are metabolized or excreted without accumulating in tissues[18]. This biocompatibility and biodegradability make SLNs a favorable choice for delivering therapeutic agents, particularly for chronic conditions like pulmonary arterial hypertension, where long-term treatment is necessary[30,7].



Fig. 2 A diagram illustrating endothelial dysfunction in pulmonary arterial hypertension (PAH) and a suggested mechanism for the extravasation of nanoparticles into the pulmonary vasculature.

3. Mechanisms of Enhancing Solubility and Bioavailability

Encapsulation of Lipophilic Phytoconstituents in SLNs

Encapsulation of lipophilic phytoconstituents in solid lipid nanoparticles (SLNs) involves incorporating these bioactive compounds into the lipid matrix during the nanoparticle preparation process[31]. There are several methods for encapsulating phytoconstituents in SLNs, including high shear homogenization, ultrasonication, and solvent emulsification-evaporation[1]. In high shear homogenization, the lipid is melted and mixed with an aqueous surfactant solution containing the phytoconstituent, followed by high-pressure homogenization to form nanoparticles[32,22]. Ultrasonication uses ultrasonic waves to create smaller particles through cavitation forces. The solvent emulsification-evaporation technique involves dissolving the lipid and the lipophilic compound in an organic solvent, which is then emulsified in an aqueous phase containing surfactants; the solvent is evaporated, leaving behind solid lipid nanoparticles encapsulating the drug[16,9]. These methods ensure that the lipophilic phytoconstituents are uniformly distributed within the solid lipid matrix, enhancing their stability and bioavailability[19].

Improvement in Solubility and Dissolution Rate

Encapsulation in SLNs significantly improves the solubility and dissolution rate of lipophilic phytoconstituents. The solid lipid matrix acts as a carrier, dispersing the poorly soluble compounds in a way that enhances their exposure to the aqueous environment[33]. When

encapsulated in SLNs, the surface area of the lipophilic compound increases dramatically due to the nanometer scale of the particles, facilitating faster dissolution[34]. Moreover, surfactants used in SLN formulations can further aid in dispersing the lipophilic molecules in the gastrointestinal fluids, promoting better solubility. The enhanced solubility and dissolution rate result in improved absorption of the phytoconstituents, contributing to their increased bioavailability[35,8].

Mechanisms of Improved Bioavailability

Enhanced Permeability and Retention Effect

SLNs improve the bioavailability of lipophilic phytoconstituents through the enhanced permeability and retention (EPR) effect[36]. The EPR effect is a phenomenon where nanoparticles preferentially accumulate in areas with leaky vasculature, such as inflamed or cancerous tissues. This effect is particularly beneficial in targeting diseased tissues like the pulmonary arteries in PAH[37]. SLNs can passively target these areas, ensuring a higher concentration of the therapeutic phytoconstituents at the site of action. Additionally, the small size of SLNs facilitates their transcytosis across cellular barriers, enhancing the permeability of the encapsulated compounds[19,3].

Protection from Enzymatic Degradation

One of the critical challenges in delivering lipophilic phytoconstituents is their susceptibility to enzymatic degradation in the gastrointestinal tract and systemic circulation. SLNs provide a protective environment that shields these compounds from metabolic enzymes[12]. The solid lipid matrix encapsulates the phytoconstituents, preventing direct exposure to enzymatic activity[38]. This protection extends the half-life of the phytoconstituents, allowing them to remain in the system longer and exert their therapeutic effects more effectively. By preventing premature degradation, SLNs enhance the overall bioavailability of the encapsulated compounds[5].

Prolonged Circulation Time

SLNs also contribute to improved bioavailability by prolonging the circulation time of lipophilic phytoconstituents. The surface of SLNs can be modified with hydrophilic polymers, such as polyethylene glycol (PEG), which provides a stealth property to the nanoparticles, reducing their recognition and clearance by the reticuloendothelial system (RES)[39]. This modification prevents rapid clearance from the bloodstream, allowing the nanoparticles to circulate for extended periods[13]. The prolonged circulation time increases the chances of the SLNs reaching their target tissues and releasing the encapsulated phytoconstituents at the desired site of action[4]. Additionally, the controlled release properties of SLNs ensure a sustained release of the therapeutic agents, maintaining effective plasma concentrations over a more extended period.SLNs enhance the solubility and bioavailability of lipophilic phytoconstituents through several mechanisms[18]. The encapsulation process improves solubility and dissolution rates by dispersing the compounds in a nanoscale lipid matrix. The EPR effect facilitates targeted delivery and enhanced permeability, while the solid lipid matrix protects the phytoconstituents from enzymatic degradation. Surface modifications can extend circulation time, further improving bioavailability[20]. These combined mechanisms make SLNs a highly effective delivery system for lipophilic phytoconstituents, offering significant therapeutic potential for conditions like pulmonary arterial hypertension[40,4].

4. Formulation Techniques for SLNs

High Shear Homogenization

High shear homogenization is a widely used method for preparing solid lipid nanoparticles (SLNs). This technique involves melting the lipid and mixing it with an aqueous surfactant solution containing the drug[41]. The mixture is then subjected to high shear forces using a

homogenizer, which breaks down the mixture into fine droplets. As the mixture cools, the lipid solidifies, forming SLNs[19]. High shear homogenization can be performed at elevated temperatures (hot homogenization) or room temperature (cold homogenization)[18]. This method is advantageous due to its simplicity, scalability, and ability to produce SLNs with a narrow size distribution[2]. However, it may not be suitable for thermolabile drugs due to the high temperatures involved in the hot homogenization process[42].

Ultrasonication

Ultrasonication is another effective method for producing SLNs, particularly suitable for small-scale preparations. In this process, the lipid and drug are first melted together, then dispersed in an aqueous surfactant solution[2,9]. The mixture is then subjected to ultrasonic waves, which generate high-energy cavitation forces, breaking down the lipid into nanometer-sized particles[5]. Ultrasonication produces SLNs with a relatively narrow size distribution and can be performed at lower temperatures, making it suitable for heat-sensitive drugs[4]. However, the process can be time-consuming, and prolonged exposure to ultrasonic waves can lead to the degradation of some compounds[43].

Solvent Emulsification-Evaporation

The solvent emulsification-evaporation technique involves dissolving the lipid and the drug in an organic solvent, which is then emulsified into an aqueous phase containing surfactants. This forms an oil-in-water emulsion[4]. The organic solvent is subsequently evaporated under reduced pressure, resulting in the solidification of the lipid and the formation of SLNs[4,5]. This method is advantageous for incorporating hydrophobic drugs and allows for precise control over particle size[3]. However, the use of organic solvents necessitates additional steps for solvent removal, and residual solvents can pose toxicity concerns[44].

Hot and Cold Homogenization

Hot and cold homogenization are variations of high shear homogenization tailored for different types of drugs[19]. In hot homogenization, the lipid and drug are melted together, and the mixture is emulsified in a hot aqueous surfactant solution. The emulsion is then subjected to high-pressure homogenization, followed by cooling to form SLNs[18,2]. This method is suitable for heat-stable drugs. Cold homogenization involves first solidifying the drug-lipid mixture by cooling it to cryogenic temperatures, followed by grinding to obtain microparticles[30]. These microparticles are then dispersed in a cold surfactant solution and subjected to high-pressure homogenization at room temperature. Cold homogenization is preferred for thermolabile drugs as it avoids exposure to high temperatures[45].

Optimization of Formulation Parameters

Particle Size and Polydispersity

The particle size and polydispersity index (PDI) are critical parameters that influence the stability, release profile, and bioavailability of SLNs[46]. Smaller particles with a narrow size distribution are preferred for enhanced cellular uptake and uniform drug release. Particle size can be controlled by adjusting the homogenization parameters, such as pressure and duration, as well as the concentration of surfactants[3,8]. A low PDI indicates a homogeneous particle size distribution, which is essential for reproducible drug delivery[47].

Zeta Potential

Zeta potential measures the surface charge of nanoparticles, which affects their stability in suspension. A high absolute value of zeta potential (either positive or negative) indicates good electrostatic repulsion between particles, preventing aggregation and ensuring colloidal stability[48]. The zeta potential can be modulated by the choice and concentration of surfactants and stabilizers[33]. For SLNs, a zeta potential greater than ±30 mV is generally considered stable, which helps maintain the dispersion of nanoparticles over extended periods[49].

Encapsulation Efficiency

Encapsulation efficiency (EE) refers to the percentage of the drug that is successfully encapsulated within the SLNs relative to the initial amount used. High encapsulation efficiency is desirable for maximizing the therapeutic efficacy of the drug[50]. EE can be influenced by factors such as the solubility of the drug in the lipid matrix, the method of preparation, and the lipid-to-drug ratio[21]. Optimizing these factors ensures that a significant portion of the drug is retained within the nanoparticles, reducing wastage and enhancing the overall effectiveness of the formulation[4,9].

5. Characterization of SLNs

Physicochemical Properties

Particle Size Analysis

Particle size is a crucial parameter influencing the stability, drug release profile, and bioavailability of solid lipid nanoparticles (SLNs)[12]. It is typically measured using dynamic light scattering (DLS), also known as photon correlation spectroscopy (PCS)[51]. DLS provides information on the average size and size distribution (polydispersity index, PDI) of the nanoparticles in a suspension. A smaller particle size generally enhances cellular uptake and improves bioavailability, while a narrow size distribution (low PDI) indicates a uniform formulation, which is essential for reproducibility and predictable drug release[18]. Optimizing particle size involves fine-tuning the formulation and processing conditions, such as homogenization pressure, surfactant concentration, and lipid composition[52].

Surface Morphology (Using TEM/SEM)

Surface morphology of SLNs is examined using electron microscopy techniques such as transmission electron microscopy (TEM) and scanning electron microscopy (SEM)[53]. TEM provides high-resolution images of the internal structure and surface characteristics of the nanoparticles, revealing details about their shape, size, and any potential aggregation[33]. SEM offers three-dimensional images of the surface, providing insights into the texture and surface features of the nanoparticles[54]. These techniques help in confirming the spherical nature of SLNs and detecting any irregularities that may affect their stability and performance. By analyzing surface morphology, researchers can optimize the formulation process to produce SLNs with the desired structural attributes[5,9].

Crystallinity (Using XRD/DSC)

Crystallinity of the lipid matrix in SLNs is a key factor affecting drug loading capacity and release behavior. X-ray diffraction (XRD) and differential scanning calorimetry (DSC) are commonly used to assess the crystalline state of the lipids[55]. XRD identifies the crystalline phases present in the lipid matrix by measuring the diffraction patterns of X-rays passing through the sample. DSC measures the heat flow associated with phase transitions, providing information on the melting point, crystallization behavior, and the degree of crystallinity of the lipids[56]. A high degree of crystallinity generally correlates with slower drug release due to the dense packing of lipid molecules, whereas a more amorphous state can facilitate faster drug release. Understanding and controlling crystallinity helps in designing SLNs with tailored release profiles[57].

In Vitro and In Vivo Studies

Release Kinetics

The release kinetics of the drug from SLNs is studied in vitro to understand how the drug is released over time[35]. This involves incubating the SLNs in a simulated physiological environment (e.g., phosphate-buffered saline, pH 7.4) and measuring the amount of drug released at various time points using techniques like high-performance liquid chromatography (HPLC)[58]. The release profile can be influenced by factors such as particle size, lipid composition, and surface properties. In vitro release studies help in predicting the

in vivo behavior of the nanoparticles, ensuring that the drug is released in a controlled and sustained manner to achieve therapeutic efficacy[59].

Stability Studies

Stability studies are essential to determine the shelf-life and robustness of SLNs. These studies involve storing the SLNs under various conditions (e.g., different temperatures, humidity levels) and periodically assessing their physicochemical properties, including particle size, zeta potential, encapsulation efficiency, and drug content[60]. Stability studies also involve evaluating the potential for drug leakage, aggregation, or changes in morphology over time. Ensuring stability is crucial for maintaining the efficacy and safety of the SLNs throughout their storage and use[61].

Bioavailability Studies in Animal Models

Bioavailability studies in animal models are conducted to evaluate the in vivo performance of SLNs. These studies involve administering the SLNs to animals (e.g., rats, mice) and measuring the plasma concentration of the drug over time using analytical methods like HPLC or mass spectrometry[62]. Bioavailability is assessed by comparing the pharmacokinetic parameters (e.g., maximum concentration, time to peak concentration, area under the curve) of the SLNs with those of conventional formulations[19]. Improved bioavailability indicates that the SLNs effectively enhance the absorption and systemic circulation of the drug[63]. Additionally, in vivo studies can provide insights into the biodistribution, metabolism, and elimination of the SLNs, helping to optimize the formulation for clinical applications[30]. The characterization of SLNs involves a comprehensive evaluation of their physicochemical properties and performance in both in vitro and in vivo settings[64]. Particle size analysis, surface morphology, and crystallinity studies provide critical information about the structural attributes of SLNs, while release kinetics, stability studies, and bioavailability studies in animal models assess their functional performance[3,7]. Thorough characterization ensures the development of robust, effective SLNs that can enhance the solubility and bioavailability of lipophilic phytoconstituents, ultimately improving therapeutic outcomes for conditions like pulmonary arterial hypertension[65,19].

6. Challenges and Future Directions

Scalability and Reproducibility of SLN Formulations

One of the significant challenges in translating solid lipid nanoparticles (SLNs) from the laboratory to clinical use is the scalability and reproducibility of their formulations[66]. While various preparation techniques like high shear homogenization, ultrasonication, and solvent emulsification-evaporation are effective on a small scale, scaling these methods up to industrial production presents difficulties[67]. High shear homogenization and ultrasonication, for instance, may not uniformly produce nanoparticles with consistent size and encapsulation efficiency when scaled up, leading to batch-to-batch variations[68]. This lack of reproducibility can affect the efficacy and safety of the final product. Additionally, large-scale production requires stringent control over parameters such as temperature, pressure, and mixing speed, which can be challenging to maintain. Addressing these issues requires the development of robust manufacturing processes that can reliably produce SLNs with uniform quality and properties[69].

Regulatory Hurdles and Approval Processes

Regulatory approval is a critical challenge in the development of SLNs for clinical use. The approval process for nanomedicines, including SLNs, is complex and stringent, requiring extensive preclinical and clinical data to demonstrate safety, efficacy, and quality[70]. Regulatory agencies like the FDA and EMA have specific guidelines for nanoparticle-based formulations, including requirements for detailed characterization, toxicity studies, and long-term stability assessments[58,9]. Meeting these regulatory standards can be time-consuming

and costly. Moreover, the lack of standardized guidelines for nanomedicines adds to the complexity, as each formulation may be subjected to different evaluation criteria. Companies must navigate these regulatory hurdles carefully, ensuring comprehensive documentation and compliance with regulatory requirements to achieve approval[29].

Future Research Avenues

Advanced Targeting Strategies

Future research in SLNs for pulmonary arterial hypertension (PAH) treatment is likely to focus on advanced targeting strategies[19]. Targeted drug delivery can enhance the therapeutic efficacy and reduce systemic side effects by directing the SLNs specifically to the diseased tissue[22]. This can be achieved through surface modification of SLNs with ligands such as antibodies, peptides, or aptamers that can recognize and bind to specific receptors on the pulmonary arterial endothelial cells[71]. Additionally, exploiting the enhanced permeability and retention (EPR) effect, which allows nanoparticles to accumulate in areas with leaky vasculature, can further improve targeting[18]. Research into stimuli-responsive SLNs, which release their payload in response to specific triggers such as pH changes or enzymatic activity, also holds promise for achieving precise drug delivery[72,73].

Personalized Medicine Approaches

Personalized medicine represents a promising direction for SLN research, where treatments are tailored to individual patients based on their genetic makeup, disease profile, and response to therapy[74]. Personalized SLN formulations can be designed to address specific patient needs, such as incorporating multiple drugs to target different pathways involved in PAH or adjusting the drug release profile to match the patient's metabolism and disease progression[75]. Advances in genomics, proteomics, and biomarker identification will facilitate the development of personalized SLNs, improving treatment outcomes and minimizing adverse effects[76,33]. Additionally, integrating diagnostic capabilities into SLNs, known as theranostics, can enable real-time monitoring of drug delivery and therapeutic efficacy, further personalizing patient care[77-80].

Combination Therapies with Other PAH Treatments

Combining SLNs with existing PAH treatments offers another avenue for enhancing therapeutic outcomes[81,82]. PAH is a multifactorial disease, and combination therapies that target different aspects of its pathophysiology can provide synergistic effects[83]. For example, SLNs encapsulating lipophilic phytoconstituents like curcumin or quercetin can be co-administered with conventional PAH drugs such as endothelin receptor antagonists or phosphodiesterase-5 inhibitors[84,85]. This approach can enhance the overall efficacy by addressing multiple pathways involved in disease progression, reducing the required dosage of each drug, and minimizing side effects[86]. Research into the optimal combinations and dosing regimens will be crucial for maximizing the benefits of such combination therapies[87,88].

7. Conclusion

Solid lipid nanoparticles (SLNs) offer a promising approach to enhance the solubility, stability, and bioavailability of lipophilic phytoconstituents, crucial for improving their therapeutic potential in treating pulmonary arterial hypertension (PAH). Techniques like high shear homogenization, ultrasonication, and solvent emulsification-evaporation are effective in SLN preparation, ensuring optimal particle characteristics and encapsulation efficiency. These advancements imply a significant impact on PAH treatment, potentially improving drug delivery precision while minimizing systemic side effects. Looking forward, addressing scalability issues, refining targeting strategies, and exploring personalized medicine

applications will likely drive further advancements in SLNs and phytoconstituent-based therapies, advancing their clinical efficacy across various medical conditions.

Conflict of interest
None

8. References

1. H. He, J. Yao, Y. Zhang, Y. Chen, K. Wang, R. J. Lee, B. Yu, and X. Zhang, "Solid lipid nanoparticles as a drug delivery system to across the blood-brain barrier," *Biochem. Biophys. Res. Commun.*, vol. 519, pp. 385-390, 2019. doi: 10.1016/j.bbrc.2019.09.017.
2. R. K. Shirodkar, L. Kumar, S. Mutalik, and S. Lewis, "Solid lipid nanoparticles and nanostructured lipid carriers: Emerging lipid based drug delivery systems," *Pharm. Chem. J.*, vol. 53, pp. 440-453, 2019. doi: 10.1007/s11094-019-02017-9.
3. P. Jain, P. Rahi, V. Pandey, S. Asati, and V. Soni, "Nanostructure lipid carriers: A modish contrivance to overcome the ultraviolet effects," *Egypt. J. Basic Appl. Sci.*, vol. 4, pp. 89-100, 2017. doi: 10.1016/j.ejbas.2017.02.001.
4. P. Jaiswal, B. Gidwani, and A. Vyas, "Nanostructured lipid carriers and their current application in targeted drug delivery," *Artif. Cells Nanomed. Biotechnol.*, vol. 44, pp. 27-40, 2016. doi: 10.3109/21691401.2014.987146.
5. S. Kaur, U. Nautyal, R. Singh, S. Singh, and A. Devi, "Nanostructure lipid carrier (NLC): The new generation of lipid nanoparticles," *Asian Pac. J. Health Sci.*, vol. 2, pp. 76-93, 2015. doi: 10.21276/apjhs.2015.2.2.14.
6. S. Sivakumar, "Therapeutic potential of chitosan nanoparticles as antibiotic delivery system: Challenges to treat multiple drug resistance," *Asian J. Pharm. Free Full Text Artic.*, vol. 10, no. 2, 2016.
7. L. Arana, L. Gallego, and I. Alkorta, "Incorporation of Antibiotics into Solid Lipid Nanoparticles: A Promising Approach to Reduce Antibiotic Resistance Emergence," *Nanomaterials*, vol. 11, p. 1251, 2021. doi: 10.3390/nano11051251.
8. S. Kumar et al., "Synthesis and optimization of ceftriaxone-loaded solid lipid nanocarriers," *Chem. Phys. Lipids*, vol. 200, pp. 126-132, 2016. doi: 10.1016/j.chemphyslip.2016.09.002.
9. R. Pignatello et al., "A method for efficient loading of ciprofloxacin hydrochloride in cationic solid lipid nanoparticles: Formulation and microbiological evaluation," *Nanomaterials*, vol. 8, p. 304, 2018. doi: 10.3390/nano8050304.
10. González-Paredes et al., "Solid lipid nanoparticles for the delivery of anti-microbial oligonucleotides," *Eur. J. Pharm. Biopharm.*, vol. 134, pp. 166-177, 2019. doi: 10.1016/j.ejpb.2018.11.017.
11. J. Porter and W. N. Charman, "Intestinal lymphatic drug transport: An update," *Adv. Drug Deliv. Rev.*, vol. 50, pp. 61-80, 2001. doi: 10.1016/S0169-409X(01)00151-X.
12. X. Wu et al., "Inhibition of intrinsic coagulation improves safety and tumor-targeted drug delivery of cationic solid lipid nanoparticles," *Biomaterials*, vol. 156, pp. 77-87, 2018. doi: 10.1016/j.biomaterials.2017.11.040.
13. S. Murgia et al., "Nanoparticles from lipid-based liquid crystals: Emulsifier influence on morphology and cytotoxicity," *J. Phys. Chem. B*, vol. 114, pp. 3518-3525, 2010. doi: 10.1021/jp9098655.
14. S. M. Hosseini et al., "Doxycycline-encapsulated solid lipid nanoparticles as promising tool against Brucella melitensis enclosed in macrophage: A pharmacodynamics study on J774A.1 cell line," *Antimicrob. Resist. Infect. Control*, vol. 8, p. 62, 2019. doi: 10.1186/s13756-019-0504-8.

15. J. Ghaderkhani et al., "Improved antibacterial function of Rifampicin-loaded solid lipid nanoparticles on Brucella abortus," *Artif. Cells Nanomed. Biotechnol.*, vol. 47, pp. 1181-1193, 2019. doi: 10.1080/21691401.2019.1593858.
16. J. Varshosaz et al., "Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery," *BioMed Res. Int.*, vol. 2013, Article ID 136859, 2013. doi: 10.1155/2013/136859.
17. S. Ghaffari et al., "Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles," *Int. J. Nanomed.*, vol. 6, p. 35, 2011.
18. F. ud Din et al., "Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors," *Int. J. Nanomed.*, vol. 12, p. 7291, 2017. doi: 10.2147/IJN.S146315.
19. L. Bayón-Cordero, I. Alkorta, and L. Arana, "Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs," *Nanomaterials*, vol. 9, p. 474, 2019. doi: 10.3390/nano9030474.
20. S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," WJPMR, vol. 8, no. 4, pp. 216–225, 2022.
21. S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in Advances in Flavonoids for Human Health and Prevention of Diseases, 2024, pp. 23-46.
22. S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in Blockchain for Healthcare Systems, 2021, pp. 61–79.
23. J.-P. Liu et al., "Smart nanoparticles improve therapy for drug-resistant tumors by overcoming pathophysiological barriers," *ActaPharmacol. Sin.*, vol. 38, pp. 1-8, 2017. doi: 10.1038/aps.2016.84.
24. O. S. Qureshi et al., "Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration," *J. Microencapsul.*, vol. 34, pp. 250-261, 2017. doi: 10.1080/02652048.2017.1337247.
25. M. Oliveira et al., "Solid lipid nanoparticles co-loaded with doxorubicin and α-tocopherol succinate are effective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell models," *Int. J. Pharm.*, vol. 512, pp. 292-300, 2016. doi: 10.1016/j.ijpharm.2016.08.049.
26. S. Nami, A. Aghebati-Maleki, and L. Aghebati-Maleki, "Current applications and prospects of nanoparticles for antifungal drug delivery," *EXCLI J.*, vol. 20, p. 562, 2021.
27. K. W. Kang et al., "Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy," *Nanomed. Nanotechnol. Biol. Med.*, vol. 6, pp. 210-213, 2010. doi: 10.1016/j.nano.2009.12.006.
28. Y. Yu, X. Cui, J. Zhao, T. Jia, B. Ren, and X. Zhang, "Effect of Entecavir Combined with AdefovirDipivoxil on Clinical Efficacy and TNF-α and IL-6 Levels in Patients with Hepatitis B Cirrhosis," *J. Oncol.*, vol. 2021, Article ID 9162346, 2021. doi: 10.1155/2021/9162346.
29. X.-g. Zhang, J. Ming, M.-w. Liu, S.-p. Jia, F.-q. Huang, and Y.-z. Dong, "Solid lipid nanoparticles loading adefovirdipivoxil for antiviral therapy," *J. Zhejiang Univ. Sci. B.*, vol. 9, pp. 506-510, 2008. doi: 10.1631/jzus.B0820047.
30. R. Delshadi, A. Bahrami, D. J. McClements, M. D. Moore, and L. Williams, "Development of nanoparticle-delivery systems for antiviral agents: A review," *J. Control Release*, vol. 331, pp. 30-44, 2021. doi: 10.1016/j.jconrel.2021.01.017.
31. B. K. J. Newton, "Impact of Pluronic F-68 vs. Tween 80 on fabrication and evaluation of acyclovir SLNs for skin delivery," *Recent Pat. Drug Deliv. Formul.*, vol. 10, pp. 207-221, 2016. doi: 10.2174/1872211310666160724213722.

32. R. Parthiban, S. Sathishkumar, and P. Ramakrishnan, "Design and evaluation of acyclovir-loaded solid lipid nanoparticles for sustained release," *Drug Invent. Today*, vol. 14, pp. 108-111, 2020.
33. S. Tulbah and W.-H. Lee, "Physicochemical Characteristics and In Vitro Toxicity/Anti-SARS-CoV-2 Activity of Favipiravir Solid Lipid Nanoparticles (SLNs)," *Pharmaceuticals*, vol. 14, p. 1059, 2021. doi: 10.3390/ph14101059.
34. F. Javan, A. Vatanara, K. Azadmanesh, M. Nabi-Meibodi, and M. Shakouri, "Encapsulation of ritonavir in solid lipid nanoparticles: In-vitro anti-HIV-1 activity using lentiviral particles," *J. Pharm. Pharmacol.*, vol. 69, pp. 1002-1009, 2017. doi: 10.1111/jphp.12737.
35. R. Kondel et al., "Effect of acyclovir solid lipid nanoparticles for the treatment of herpes simplex virus (HSV) infection in an animal model of HSV-1 infection," *Pharm. Nanotechnol.*, vol. 7, pp. 389-403, 2019. doi: 10.2174/2211738507666190829161737.
36. S. Hassanipour, M. Arab-Zozani, B. Amani, F. Heidarzad, M. Fathalipour, and R. Martinez-de-Hoyo, "The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials," *Sci. Rep.*, vol. 11, Article ID 11022, 2021. doi: 10.1038/s41598-021-90551-6.
37. L. P. Kaur, "Topical gel: A recent approach for novel drug delivery," *Asian J. Biomed. Pharm. Sci.*, vol. 3, p. 1, 2013.
38. C. M. Lee and H. I. Maibach, "Deep percutaneous penetration into muscles and joints," *J. Pharm. Sci.*, vol. 95, pp. 1405-1413, 2006. doi: 10.1002/jps.20666.
39. N. Dudhipala and A. A. Ay, "Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections," *Chem. Phys. Lipids*, vol. 232, p. 104953, 2020. doi: 10.1016/j.chemphyslip.2020.104953.
40. S. El-Housiny et al., "Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: Formulation and clinical study," *Drug Deliv.*, vol. 25, pp. 78-90, 2018. doi: 10.1080/10717544.2017.1413444.
41. C. Carbone et al., "Dual-drugs delivery in solid lipid nanoparticles for the treatment of Candida albicans mycosis," *Colloids Surf. B Biointerfaces*, vol. 186, p. 110705, 2020. doi: 10.1016/j.colsurfb.2019.110705.
42. M. Ruhnke, "Antifungal stewardship in invasive Candida infections," *Clin. Microbiol. Infect.*, vol. 20, pp. 11-18, 2014. doi: 10.1111/1469-0691.12622.
43. V. Kumar *et al.*, “Neuroprotective Effect of Boswelliaserrata against 3-NP Induced Experimental Huntington’s Disease,” *Current bioactive compounds*, vol. 20, Jan. 2024, doi: https://doi.org/10.2174/0115734072272233231119161319.
44. P. Bhatt, V. Kumar, S. Singh, and KunalKanojia, “Climatic/Meteorological Conditions and Their Role in Biological Contamination,” pp. 56–88, Jun. 2024, doi: https://doi.org/10.1002/9781394178964.ch4.
45. Dharmendra Bhati *et al.*, “FUSED AND SUBSTITUTED PYRIMIDINE DERIVATIVES AS POTENT ANTICANCER AGENTS,” *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.749.
46. K. J. Mangala *et al.*, “NANOCELLULOSE: A VERSATILE AND SUSTAINABLE CARRIER FOR DRUG AND BIOACTIVE COMPOUNDS,” *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.553.
47. Rohit Kumar Trivedi *et al.*, “REVOLUTIONIZING DRUG DELIVERY THROUGH 3D PRINTING TECHNOLOGY: CURRENT ADVANCES AND FUTURE

DIRECTIONS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.521.
48. H. Rastogi, P. Bhatt, S. Garg, S. Kamboj, V. Deva, and R. Goel, "EXPLORING THE POTENTIAL OF QUANTUM DOTS AS LUMINOUS PROBES FOR TARGETED DRUG DELIVERY AND BIOIMAGING IN CLINICAL DIAGNOSTICS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.457.
49. M. shama, "CRISPR-Cas9 gene editing in pharmaceuticals : Current applications and future prospects," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1655.
50. S. Arora, Saiphali, G. Dharmamoorthy Dharmendra Bhati, T. Gupta, and P. Bhatt, "Advancements in peptide-based therapeutics: Design, synthesis and clinical applications," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1415.
51. M. Singhal et al., "Formulation development and characterization of powder for oral suspension containing H2 blocker drug to combat GERD and peptic ulcer," NeuroQuantology, vol. 20, no. 11, pp. 1258, 2022.
52. S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.
53. V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," International Journal of Pharmaceutical Sciences and Research, vol. 11, no. 5, pp. 2193–2198, 2020.
54. A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," GSC biol pharm sci, vol. 19, no. 3, pp. 148–155, 2022.
55. B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., Encyclopedia of green materials. Singapore: Springer Nature Singapore, 2022.
56. P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy- A review," Am J PharmTech Res, vol. 9, no. 3, pp. 321–331, 2019.
57. P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in The Flavonoids, 2024, pp. 131-152.
58. P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloaesculenta) starch," ACS Omega, vol. 8, no. 33, pp. 30294–305, 2023.
59. P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," Pharmaceutics, vol. 15, no. 8, p. 2066, 2023.
60. P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," Pharma Science Monitor, vol. 9, no. 2, 2018.
61. P. Bhatt et al., "Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery," Int J Pharm Investig, vol. 11, no. 1, pp. 69–75, 2021.
62. P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," The Chinese Journal of Artificial Intelligence, 2023.
63. P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in Blockchain for Healthcare Systems, 2021, pp. 97–113.

64. P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium–A Review," World J. Pharm. Pharm. Sci, vol. 7, no. 9, pp. 271-287, 2018.
65. C. Goyal et al., "Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents," Res J Pharm Technol, pp. 5078–5083, 2022.
66. T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," J Pharm Res Int, pp. 70–78, 2021.
67. M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," Phytomed Plus, vol. 3, no. 2, p. 100445, 2023.
68. A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," J Chem Pharm Sci, vol. 12, no. 03, pp. 71–78, 2019.
69. M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," Nat Prod J, 2022.
70. M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," ACS Omega, vol. 7, no. 40, pp. 35506–35514, 2022.
71. M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," ACS Omega, vol. 8, no. 13, pp. 11750–11767, 2023.
72. Pankaj, "Anti-cancer cyclodextrinnanocapsules based formulation development for lung chemotherapy," J Pharm Res Int, pp. 54–63, 2021.
73. Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," J Pharm Res Int, pp. 21–29, 2021.
74. V. Raghuwanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," Journal of Pharmaceutical Negative Results, pp. 1811-1820, 2022.
75. K. K. Sahu et al., "Utility of nanomaterials in wound management," in Nanotechnological Aspects for Next-Generation Wound Management, 2024, pp. 101–130.
76. S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," J Infect Public Health, vol. 15, no. 5, pp. 566–572, 2022.
77. S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," J Pharm Res Int, pp. 5–13, 2021.
78. S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," Journal of Pharmaceutical Research International, vol. 32, no. 36, pp. 82-88, 2022.
79. S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," Journal of Pharmaceutical Negative Results, pp. 1463-1469, 2022.
80. R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in 2023 12th International Conference on System Modeling& Advancement in Research Trends (SMART), 2023, pp. 556-561.
81. P. Bhatt et al., “Impact of Cross-Linking on the Physicochemical and Physiological Characteristics of Barnyard Millet (Echinochloafrumentacea) Grains Starch,” Stärke/Starch, May 2024, doi: https://doi.org/10.1002/star.202300285.
82. V. Kumar et al., “Ultrasound assisted techniques for starch modification to develop novel drug delivery systems: A comprehensive study,” Journal of bioactive and compatible polymers, May 2024, doi: https://doi.org/10.1177/08839115241249143.

83. Y. Duan, A. Dhar, C. Patel, M. Khimani, S. Neogi, P. Sharma, N. S. Kumar, and R. L. Vekariya, "A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems," *RSC Adv.*, vol. 10, pp. 26777-26791, 2020. doi: 10.1039/D0RA03491F.
84. S. ScioliMontoto, G. Muraca, and M. E. Ruiz, "Solid lipid nanoparticles for drug delivery: Pharmacological and biopharmaceutical aspects," *Front. Mol. Biosci.*, vol. 7, p. 319, 2020. doi: 10.3389/fmolb.2020.587997.
85. R. K. Tekade, R. Maheshwari, M. Tekade, and M. B. Chougule, "Solid lipid nanoparticles for targeting and delivery of drugs and genes," in *Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes*. Amsterdam, The Netherlands: Elsevier, 2017, pp. 256-286.
86. N. Naseri, H. Valizadeh, and P. Zakeri-Milani, "Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application," *Adv. Pharmaceut. Bull.*, vol. 5, p. 305, 2015. doi: 10.15171/apb.2015.043.
87. V. Mishra, K. K. Bansal, A. Verma, N. Yadav, S. Thakur, K. Sudhakar, and J. M. Rosenholm, "Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems," *Pharmaceutics*, vol. 10, p. 191, 2018. doi: 10.3390/pharmaceutics10040191.
88. R. Thatipamula, C. Palem, R. Gannu, S. Mudragada, and M. Yamsani, "Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers," *Daru J. Fac. Pharm. Tehran Univ. Med. Sci.*, vol. 19, p. 23, 2011.